Provided by Tiger Fintech (Singapore) Pte. Ltd.

Corvus Pharmaceuticals

7.04
-0.6100-7.97%
Post-market: 6.94-0.1000-1.42%19:47 EDT
Volume:989.96K
Turnover:7.10M
Market Cap:524.58M
PE:-6.93
High:7.70
Open:7.52
Low:6.90
Close:7.65
52wk High:10.00
52wk Low:2.54
Shares:74.51M
Float Shares:57.36M
Volume Ratio:0.77
T/O Rate:1.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0164
EPS(LYR):-1.0214
ROE:-68.67%
ROA:-28.84%
PB:6.54
PE(LYR):-6.89

Loading ...

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

GlobeNewswire
·
Oct 17

Corvus Pharmaceuticals Initiated at Overweight by Barclays

Dow Jones
·
Oct 13

Corvus Pharmaceuticals initiated with an Overweight at Barclays

TIPRANKS
·
Oct 13

Corvus Pharmaceuticals (CRVS) Has a New Rating from Barclays

TIPRANKS
·
Oct 13

Corvus Pharmaceuticals Files Initial Beneficial Ownership Statement for Director David Scott Moore

Reuters
·
Oct 07

Press Release: Corvus Pharmaceuticals Appoints David Moore to Board of Directors

Dow Jones
·
Oct 03

While institutions invested in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) benefited from last week's 12% gain, individual investors stood to gain the most

Simply Wall St.
·
Sep 25

Corvus Pharmaceuticals : Oppenheimer Cuts Target Price to $15 From $17

THOMSON REUTERS
·
Aug 08

Corvus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 08

Corvus Pharma Q2 EPS $(0.10) Beats $(0.13) Estimate

Benzinga
·
Aug 08

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

GlobeNewswire
·
Aug 08

Corvus Pharmaceuticals Inc expected to post a loss of 14 cents a share - Earnings Preview

Reuters
·
Aug 06

Corvus Pharmaceuticals Inc expected to post a loss of 14 cents a share - Earnings Preview

Reuters
·
Aug 01

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025

GlobeNewswire
·
Aug 01

Corvus 'Undervalued' Following Atopic Dermatitis Data From Apogee, Mizuho Securities Says

MT Newswires Live
·
Jul 08

Director and 10% Owner Peter A. Thompson Reports Disposal of Common Shares of Corvus Pharmaceuticals Inc

Reuters
·
Jul 02

Corvus Pharmaceuticals Gets China Nod to Begin Atopic Dermatitis Drug Trial

MT Newswires Live
·
Jun 25

BRIEF-Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval For A Phase 1B/2 Clinical Trial Of Soquelitinib

Reuters
·
Jun 25

Corvus Pharmaceuticals Inc. Conducted Annual Stockholders Meeting

Reuters
·
Jun 14

Corvus Pharmaceuticals Unveils Promising Interim Results from Phase 1 Trial of Soquelitinib for Atopic Dermatitis

Reuters
·
Jun 04